<?xml version='1.0' encoding='utf-8'?>
<document id="21125264"><sentence text="Power estimation using a population pharmacokinetics model with optimal design by clinical trial simulations: application in pharmacokinetic drug-drug interaction studies." /><sentence text="The aim of this article was to determine the power for pharmacokinetic interaction investigations using population a pharmacokinetic modelling approach with optimal sampling designs and clinical trial simulations" /><sentence text="" /><sentence text="A clinical trial simulation approach was proposed to estimate the power for pharmacokinetic effects in drug-drug interaction (DDI) studies" /><sentence text=" This approach consisted of: (1) population pharmacokinetic (PK) model(s) was characterised for the drug(s) studied; (2) D-optimal design strategy was applied based on these model(s) to determine optimal sampling times for DDI investigation; (3) clinical trial simulations under particular study designs, for example a randomised parallel design, were used to evaluate the sample size needed for studying PK interaction" /><sentence text=" The approach was described using an example investigating the impact of a new anti-inflammatory drug on methotrexate (MTX) exposure in rheumatoid arthritis (RA) patients"><entity charOffset="105-117" id="DDI-PubMed.21125264.s6.e0" text="methotrexate" /><entity charOffset="119-122" id="DDI-PubMed.21125264.s6.e1" text="MTX" /><pair ddi="false" e1="DDI-PubMed.21125264.s6.e0" e2="DDI-PubMed.21125264.s6.e0" /><pair ddi="false" e1="DDI-PubMed.21125264.s6.e0" e2="DDI-PubMed.21125264.s6.e1" /></sentence><sentence text="" /><sentence text="The power for evaluating PK interaction largely depended on the interindividual variability (IIV) in PK parameters" /><sentence text=" Residual variability was also influential to a lesser degree in the sample size determination using the proposed approach" /><sentence text=" It required 40-60 participants for scenarios where IIV was relatively low in order to achieve 90% power" /><sentence text=" However, a sample size of 80 individuals was required to reach 90% power where both IIV and residual variances were high" /><sentence text=" Under the same IIV assumptions, the proposed approach in general required a smaller sample size compared with the standard noncompartmental analysis method with intensive blood samples to attain the target power" /><sentence text=" When IIV was low, the difference in the power between the two approaches was relatively small" /><sentence text="" /><sentence text="Population PK modelling with optimal design and clinical trial simulation to determine sample size when designing drug-drug interaction studies was efficient and cost effective" /><sentence text="" /></document>